Approval · Notice of Compliance 26335 · 2021
STRIBILD: Notice of Compliance 26335
Issued July 27, 2021
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 26335
- Date
- July 27, 2021
- Company
- Gilead Sciences Canada IncMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- To update the drug interactions in Product Monograph and update to the 2020 Product Monograph master template.
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| STRIBILD | Not yet assigned | — |
Medicinal ingredients
- EMTRICITABINE 200 MG per TAB
- TENOFOVIR DISOPROXIL FUMARATE 300 MG per TAB
- ELVITEGRAVIR 150 MG per TAB
- COBICISTAT 150 MG per TAB